Attorney Discusses Cosmetic Trespasses On Drug Turf Leading To FDA Action

The line that divides drugs from personal care is "fuzzy," but companies can begin to understand what marketing claims are acceptable to FDA by learning from the mistakes of others, Ivan Wasserman, partner at Manatt, Phelps & Phillips, suggests